Methods for selecting treatment regimens and predicting outcomes in cancer patients
CA 2476352 A1 · Owner: Kates, Ronald E. · Inventors: Foekens, John A.; Schmitt, Manfred; Harbeck, Nadia
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to methods for determining a treatment regimen beyond removal of tumor tissue for node negative or node positive breast cancer patient. The method comprises measuring the levels of urokinase-type plasminogen activator (uPA) and plasminogen activator-1 (PAI-1) in a subject preferably a tumor; and based upon the values predicting the expected benefit , including disease-free survival and/or overall survival for the patient without treatment (beyond the surgical removal of tumor tissue) or with a particular treatment and using that information to select a treatment regimen for the subject. High risk subject is identified by high levels of both uPA and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 13, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 13, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 13, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.